The U.S. will begin a five-year pilot program to allow Medicare and Medicaid to cover weight-loss drugs like Ozempic and Wegovy. Medicaid coverage starts in 2026, Medicare in 2027. The initiative includes lifestyle support requirements and aims to combat obesity, though concerns over cost and long-term impact remain.





